ArticleFrontiers in oncology2023

The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.

Yue Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.